Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
GlobeNewswire
- Top-line Results Expected in the Second Half of 2024 -
PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- *Cognition..